Literature DB >> 11508904

The performance and problems of the Turkish pharmaceutical industry: is there a need to develop a national drug policy?

A Kisa1.   

Abstract

Turkey has a big pharmaceutical industry-of the drugs consumed there, 90% are manufactured domestically. Eighty percent of this manufacturing is run by foreign companies. In this study, the performance of the Turkish pharmaceutical industry in terms of the technology and production is examined and compared with that of some other countries, and the importance of the essential drugs list and national drug policy is discussed. At the end of the study, strategies are suggested toward meeting the main current challenges in the Turkish pharmaceutical industry.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11508904     DOI: 10.1023/a:1010685207582

Source DB:  PubMed          Journal:  J Med Syst        ISSN: 0148-5598            Impact factor:   4.460


  6 in total

1.  National drug formularies: lessons from Latin America.

Authors:  A A LeRoy; M L Morse
Journal:  Drug Inf J       Date:  1983

2.  Why does Australia have no national drug policy?

Authors:  A J Smith
Journal:  Med J Aust       Date:  1992-03-02       Impact factor: 7.738

3.  Essential drugs for all.

Authors:  H K Hye
Journal:  World Health Forum       Date:  1988

4.  Essential and non-essential drugs marketed by the 20 largest European pharmaceutical companies in developing countries.

Authors:  R Hartog
Journal:  Soc Sci Med       Date:  1993-10       Impact factor: 4.634

5.  Essential drugs and registration of pharmaceuticals: the Sri Lankan experience.

Authors:  K Weerasuriya
Journal:  Bull World Health Organ       Date:  1993       Impact factor: 9.408

6.  WHO's programme on essential drugs. Background, implementation, present state and prospectives.

Authors:  P K Lunde
Journal:  Dan Med Bull       Date:  1984-11
  6 in total
  1 in total

1.  A survey of pharmaceutical company representative interactions with doctors in Libya.

Authors:  Mustafa A Alssageer; Stefan R Kowalski
Journal:  Libyan J Med       Date:  2012-09-18       Impact factor: 1.657

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.